Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: Bill Coenen who wrote (2734)	11/3/1998 7:08:00 PM
From: Brian Moloney	Read Replies (1) \| Respond to of 3725

Obviously, this is another in a long line of good news publications for those of us who believe in the technology. I think that this is even a lot different from the previous articles. I don't remember anarticle talking about the benefits for those patients with heart failure before, nor do I remember an article that speaks specifically to cost savings estimates. The two negatives that occur to me are first, the article is from UCLA which has always been pro-imatron. I'm waiting for the article from the cardiology center that says essentially, "Boy, have I been wrong about this." The other thing is that the savings come at the expense of cardiologists many of whom are anti-EBCT as it is. We'll see if management can capitalize on this news and sell some machines.